Key Updates In The Management Of Patients With Vitiligo
Edward Lain, M.D., MBA, discusses how vitiligo is a complex autoimmune condition involving melanocyte destruction through both innate and adaptive immune mechanisms, presenting as either segmental or nonsegmental forms with significant psychosocial impacts, and requiring multidisciplinary care including dermatologic treatment with FDA-approved ruxolitinib cream, systemic therapies and light-based treatments while addressing comorbidities like thyroid disease and providing psychological support for patients dealing with the visible nature of this unpredictable condition.
EP. 1: Vitiligo Presentation in Different Patient Populations
June 30th 2025An expert discusses how vitiligo involves a complex autoimmune mechanism where the body’s immune system destroys melanocytes, presenting as either segmental vitiligo (rapid, localized to one body area) or nonsegmental vitiligo (slower, scattered patches), with treatment success depending on the presence of pigmented hairs in affected areas.
Watch
EP. 2: Importance of Early Diagnosis of Vitiligo
June 30th 2025An expert discusses how early diagnosis of vitiligo is primarily important for limiting the area requiring repigmentation, while explaining that genetic predisposition, autoimmune thyroid disease and skin trauma are key risk factors for developing the condition.
Watch
